MedTrace Logo

C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

NCT01397864 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 181

Last updated 2025-04-08

No results posted yet for this study

Summary

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

Conditions

Interventions

DRUG

rhC1INH or pdC1INH

C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)

Sponsors & Collaborators

  • Pharming Technologies B.V.

    lead INDUSTRY

Principal Investigators

  • Anurag Relan, MD · Pharming Technologies BV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2024-10-18
Completion
2024-12-10

Countries

  • Bulgaria
  • Croatia
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • North Macedonia
  • Norway
  • Poland
  • Slovakia
  • Slovenia
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397864 on ClinicalTrials.gov